{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:40:54Z","timestamp":1786995654968,"version":"build-2736575974"},"reference-count":134,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.phrs.2022.106474","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T01:10:33Z","timestamp":1664327433000},"page":"106474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Negative allosteric modulation of CB1 cannabinoid receptor signaling suppresses opioid-mediated reward"],"prefix":"10.1016","volume":"185","author":[{"given":"Vishakh","family":"Iyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Rangel-Barajas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor J.","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Cantwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon D.","family":"Crystal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Mackie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George V.","family":"Rebec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh A.","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea G.","family":"Hohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.phrs.2022.106474_bib1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.31887\/DCNS.2017.19.3\/tcicero","article-title":"The prescription opioid epidemic: a review of qualitative studies on the progression from initial use to abuse","volume":"19","author":"Cicero","year":"2017","journal-title":"Dialog-. Clin. Neurosci."},{"key":"10.1016\/j.phrs.2022.106474_bib2","unstructured":"F. Ahmad, L. Rossen, P. Sutton, Provisional drug overdose death counts National Center for Health Statistics. 2021, Statistics, Centers for Disease Control and Prevention (CDC). (2021)."},{"issue":"11","key":"10.1016\/j.phrs.2022.106474_bib3","doi-asserted-by":"crossref","first-page":"290","DOI":"10.15585\/mmwr.mm6911a4","article-title":"Drug and opioid-involved overdose deaths - United States, 2017-2018","volume":"69","author":"Wilson","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.phrs.2022.106474_bib4","unstructured":"Centers for Disease Control and Prevention, Overdose Deaths Accelerating During COVID-19, \u3008https:\/\/www.cdc.gov\/media\/releases\/2020\/p1218-overdose-deaths-covid-19.html\u3009 (2020)."},{"issue":"6","key":"10.1016\/j.phrs.2022.106474_bib5","first-page":"588","article-title":"Cancer pain management: opioid analgesics, Part 2","volume":"8","author":"Wickham","year":"2017","journal-title":"J. Adv. Pr. Oncol."},{"issue":"7","key":"10.1016\/j.phrs.2022.106474_bib6","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.mayocp.2015.04.010","article-title":"Opioid analgesics","volume":"90","author":"Jamison","year":"2015","journal-title":"Mayo Clin. Proc."},{"issue":"4","key":"10.1016\/j.phrs.2022.106474_bib7","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.neuron.2011.02.001","article-title":"The doctor's dilemma: opiate analgesics and chronic pain","volume":"69","author":"Fields","year":"2011","journal-title":"Neuron"},{"issue":"11","key":"10.1016\/j.phrs.2022.106474_bib8","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1503\/cmaj.051528","article-title":"Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects","volume":"174","author":"Furlan","year":"2006","journal-title":"CMAJ"},{"key":"10.1016\/j.phrs.2022.106474_bib9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ypmed.2015.04.003","article-title":"Prescription opioid abuse: problems and responses","volume":"80","author":"Compton","year":"2015","journal-title":"Prev. Med."},{"issue":"12","key":"10.1016\/j.phrs.2022.106474_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.27481","article-title":"Comparison of opioids prescribed for patients at risk for opioid misuse before and after publication of the centers for disease control and prevention's opioid prescribing guidelines","volume":"3","author":"Scherrer","year":"2020","journal-title":"JAMA Netw. Open"},{"issue":"4","key":"10.1016\/j.phrs.2022.106474_bib11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.tins.2006.01.008","article-title":"Involvement of the endocannabinoid system in drug addiction","volume":"29","author":"Maldonado","year":"2006","journal-title":"Trends Neurosci."},{"issue":"1","key":"10.1016\/j.phrs.2022.106474_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainresrev.2006.05.003","article-title":"An endocannabinoid mechanism in relapse to drug seeking: a review of animal studies and clinical perspectives","volume":"53","author":"Fattore","year":"2007","journal-title":"Brain Res. Rev."},{"issue":"1","key":"10.1016\/j.phrs.2022.106474_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s002130000481","article-title":"Cannabinoid receptors and reward in the rat: a conditioned place preference study","volume":"151","author":"Cheer","year":"2000","journal-title":"Psychopharmacol. (Berl.)"},{"issue":"5","key":"10.1016\/j.phrs.2022.106474_bib14","first-page":"375","article-title":"The endocannabinoid system and its possible role in neurobiology of psychiatric disorders","volume":"48","author":"Caroti","year":"2013","journal-title":"Riv. Psichiatr"},{"issue":"2","key":"10.1016\/j.phrs.2022.106474_bib15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.pbb.2005.01.032","article-title":"Endocannabinoid signaling system and brain reward: emphasis on dopamine","volume":"81","author":"Gardner","year":"2005","journal-title":"Pharm. Biochem Behav."},{"issue":"3","key":"10.1016\/j.phrs.2022.106474_bib16","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1523\/JNEUROSCI.21-03-00823.2001","article-title":"Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus","volume":"21","author":"Rodriguez","year":"2001","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.phrs.2022.106474_bib17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.neuroscience.2004.05.015","article-title":"Compartment-specific localization of cannabinoid 1 (CB1) and mu-opioid receptors in rat nucleus accumbens","volume":"127","author":"Pickel","year":"2004","journal-title":"Neuroscience"},{"issue":"5","key":"10.1016\/j.phrs.2022.106474_bib18","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1073\/pnas.87.5.1932","article-title":"Cannabinoid receptor localization in brain","volume":"87","author":"Herkenham","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.phrs.2022.106474_bib19","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/S0014-2999(99)00656-1","article-title":"Lack of morphine-induced dopamine release in the nucleus accumbens of cannabinoid CB(1) receptor knockout mice","volume":"383","author":"Mascia","year":"1999","journal-title":"Eur. J. Pharm."},{"issue":"3","key":"10.1016\/j.phrs.2022.106474_bib20","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0022-3565(24)29469-6","article-title":"Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice","volume":"298","author":"Lichtman","year":"2001","journal-title":"J. Pharm. Exp. Ther."},{"issue":"5400","key":"10.1016\/j.phrs.2022.106474_bib21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1126\/science.283.5400.401","article-title":"Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice","volume":"283","author":"Ledent","year":"1999","journal-title":"Science"},{"issue":"22","key":"10.1016\/j.phrs.2022.106474_bib22","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0024-3205(00)00547-6","article-title":"Long-term treatment with SR141716A, the CB1 receptor antagonist, influences morphine withdrawal syndrome","volume":"66","author":"Rubino","year":"2000","journal-title":"Life Sci."},{"issue":"8","key":"10.1016\/j.phrs.2022.106474_bib23","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1038\/sj.bjp.0703990","article-title":"Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction","volume":"132","author":"Mas-Nieto","year":"2001","journal-title":"Br. J. Pharm."},{"issue":"1","key":"10.1016\/j.phrs.2022.106474_bib24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1748-1716.2011.02402.x","article-title":"CB1 receptor antagonists: new discoveries leading to new perspectives","volume":"205","author":"Kirilly","year":"2012","journal-title":"Acta Physiol. (Oxf.)"},{"issue":"12","key":"10.1016\/j.phrs.2022.106474_bib25","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/nrd2775","article-title":"End of the line for cannabinoid receptor 1 as an anti-obesity target?","volume":"7","author":"Jones","year":"2008","journal-title":"Nat. Rev. Drug Disco"},{"issue":"5","key":"10.1016\/j.phrs.2022.106474_bib26","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1467-789X.2009.00581.x","article-title":"Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta\u2010analysis","volume":"10","author":"Johansson","year":"2009","journal-title":"Obes. Rev."},{"issue":"1","key":"10.1016\/j.phrs.2022.106474_bib27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.beem.2008.09.003","article-title":"Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression","volume":"23","author":"Moreira","year":"2009","journal-title":"Best. Pr. Res Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.phrs.2022.106474_bib28","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1124\/mol.105.016162","article-title":"Allosteric modulation of the cannabinoid CB1 receptor","volume":"68","author":"Price","year":"2005","journal-title":"Mol. Pharm."},{"issue":"9","key":"10.1016\/j.phrs.2022.106474_bib29","doi-asserted-by":"crossref","first-page":"5828","DOI":"10.1074\/jbc.M113.478495","article-title":"Allosteric modulation of a cannabinoid G protein-coupled receptor: binding site elucidation and relationship to G protein signaling","volume":"289","author":"Shore","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.phrs.2022.106474_bib30","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/FBP.0000000000000027","article-title":"In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569","volume":"25","author":"Gamage","year":"2014","journal-title":"Behav. Pharm."},{"key":"10.1016\/j.phrs.2022.106474_bib31","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.drugalcdep.2014.08.004","article-title":"Effects of the cannabinoid CB(1) receptor allosteric modulator ORG 27569 on reinstatement of cocaine- and methamphetamine-seeking behavior in rats","volume":"143","author":"Jing","year":"2014","journal-title":"Drug Alcohol Depend."},{"issue":"5","key":"10.1016\/j.phrs.2022.106474_bib32","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/sj.bjp.0707347","article-title":"Kai In, PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats","volume":"152","author":"Horswill","year":"2007","journal-title":"Br. J. Pharm."},{"issue":"2","key":"10.1016\/j.phrs.2022.106474_bib33","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/bph.12599","article-title":"Positive allosteric modulators of the mu-opioid receptor: a novel approach for future pain medications","volume":"172","author":"Burford","year":"2015","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.phrs.2022.106474_bib34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.neuropharm.2017.05.018","article-title":"Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities","volume":"124","author":"Khurana","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2022.106474_bib35","article-title":"New perspectives on the role of the neurosteroid pregnenolone as an endogenous regulator of type-1 cannabinoid receptor (CB1R) activity and function","author":"Raux","year":"2021","journal-title":"J. Neuroendocr."},{"issue":"1","key":"10.1016\/j.phrs.2022.106474_bib36","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1089\/can.2015.0005","article-title":"Allosteric modulators of the CB1 cannabinoid receptor: a structural update review","volume":"1","author":"Morales","year":"2016","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.phrs.2022.106474_bib37","unstructured":"G.A. Thakur, R.B. Tichkule, P.M. Kulkarni, A.R. Kulkarni, Allosteric modulators of the cannabinoid 1 receptor, U.S. Patent US9926275B2, Northeastern University, U.S. Patent Office, 2018."},{"issue":"35","key":"10.1016\/j.phrs.2022.106474_bib38","doi-asserted-by":"crossref","first-page":"8821","DOI":"10.1523\/JNEUROSCI.2225-08.2008","article-title":"Preferential enhancement of dopamine transmission within the nucleus accumbens shell by cocaine is attributable to a direct increase in phasic dopamine release events","volume":"28","author":"Aragona","year":"2008","journal-title":"J. Neurosci."},{"issue":"11","key":"10.1016\/j.phrs.2022.106474_bib39","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/nn1578","article-title":"Is there a common molecular pathway for addiction?","volume":"8","author":"Nestler","year":"2005","journal-title":"Nat. Neurosci."},{"issue":"2","key":"10.1016\/j.phrs.2022.106474_bib40","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0304-3959(83)90201-4","article-title":"Ethical guidelines for investigations of experimental pain in conscious animals","volume":"16","author":"Zimmermann","year":"1983","journal-title":"Pain"},{"issue":"7","key":"10.1016\/j.phrs.2022.106474_bib41","article-title":"Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0","volume":"18","author":"Percie du Sert","year":"2020","journal-title":"PLoS Biol."},{"issue":"13","key":"10.1016\/j.phrs.2022.106474_bib42","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1038\/npp.2015.148","article-title":"A cannabinoid CB1 receptor-positive allosteric modulator reduces neuropathic pain in the mouse with no psychoactive effects","volume":"40","author":"Ignatowska-Jankowska","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2022.106474_bib43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/bs.mie.2017.06.027","article-title":"Protocols and good operating practices in the study of cannabinoid receptors","volume":"593","author":"Console-Bram","year":"2017","journal-title":"Methods Enzym."},{"issue":"54","key":"10.1016\/j.phrs.2022.106474_bib44","article-title":"Positive allosteric modulation of CB1 cannabinoid receptor signaling enhances morphine antinociception and attenuates morphine tolerance without enhancing morphine- induced dependence or reward","volume":"13","author":"Slivicki","year":"2020","journal-title":"Front. Mol. Neurosci."},{"issue":"3","key":"10.1016\/j.phrs.2022.106474_bib45","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1124\/jpet.118.252288","article-title":"Brain-permeant and -impermeant inhibitors of fatty acid amide hydrolase synergize with the opioid analgesic morphine to suppress chemotherapy-induced neuropathic nociception without enhancing effects of morphine on gastrointestinal transit","volume":"367","author":"Slivicki","year":"2018","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.phrs.2022.106474_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173544","article-title":"The cannabinoid CB2 receptor agonist LY2828360 synergizes with morphine to suppress neuropathic nociception and attenuates morphine reward and physical dependence","volume":"886","author":"Iyer","year":"2020","journal-title":"Eur. J. Pharm."},{"issue":"5","key":"10.1016\/j.phrs.2022.106474_bib47","doi-asserted-by":"crossref","DOI":"10.1111\/adb.13220","article-title":"Inhibition of PSD95-nNOS protein-protein interactions decreases morphine reward and relapse vulnerability in rats","volume":"27","author":"Oliva","year":"2022","journal-title":"Addict. Biol."},{"issue":"5","key":"10.1016\/j.phrs.2022.106474_bib48","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.biopsych.2014.04.009","article-title":"Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal","volume":"77","author":"Deng","year":"2015","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.phrs.2022.106474_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147620","article-title":"Impact of genetic reduction of NMNAT2 on chemotherapy-induced losses in cell viability in vitro and peripheral neuropathy in vivo","volume":"11","author":"Slivicki","year":"2016","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.phrs.2022.106474_bib50","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.biopsych.2017.06.032","article-title":"Positive allosteric modulation of cannabinoid receptor type 1 suppresses pathological pain without producing tolerance or dependence","volume":"84","author":"Slivicki","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2022.106474_bib51","article-title":"A limited access oral oxycodone paradigm produces physical dependence and mesocorticolimbic region-dependent increases in DeltaFosB expression without preference","author":"Iyer","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2022.106474_bib52","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3389\/fnmol.2020.00054","article-title":"Positive allosteric modulation of CB1 cannabinoid receptor signaling enhances morphine antinociception and attenuates morphine tolerance without enhancing morphine- induced dependence or reward","volume":"13","author":"Slivicki","year":"2020","journal-title":"Front Mol. Neurosci."},{"issue":"1\u20132","key":"10.1016\/j.phrs.2022.106474_bib53","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0166-4328(02)00284-X","article-title":"Modeling fast dopamine neurotransmission in the nucleus accumbens during behavior","volume":"137","author":"Garris","year":"2002","journal-title":"Behav. Brain Res."},{"issue":"5","key":"10.1016\/j.phrs.2022.106474_bib54","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1037\/bne0000012","article-title":"Extinction and reinstatement of phasic dopamine signals in the nucleus accumbens core during Pavlovian conditioning","volume":"128","author":"Sunsay","year":"2014","journal-title":"Behav. Neurosci."},{"issue":"2","key":"10.1016\/j.phrs.2022.106474_bib55","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1037\/0735-7044.122.2.358","article-title":"Real-time dopamine efflux in the nucleus accumbens core during Pavlovian conditioning","volume":"122","author":"Sunsay","year":"2008","journal-title":"Behav. Neurosci."},{"issue":"13","key":"10.1016\/j.phrs.2022.106474_bib56","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1021\/ac00164a006","article-title":"Fast-scan voltammetry of biogenic amines","volume":"60","author":"Baur","year":"1988","journal-title":"Anal. Chem."},{"issue":"2","key":"10.1016\/j.phrs.2022.106474_bib57","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1152\/jn.00413.2010","article-title":"Sensitization of rapid dopamine signaling in the nucleus accumbens core and shell after repeated cocaine in rats","volume":"104","author":"Addy","year":"2010","journal-title":"J. Neurophysiol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106474_bib58","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/jnc.12197","article-title":"Amphetamine augments vesicular dopamine release in the dorsal and ventral striatum through different mechanisms","volume":"125","author":"Avelar","year":"2013","journal-title":"J. Neurochem"},{"issue":"3","key":"10.1016\/j.phrs.2022.106474_bib59","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1124\/jpet.116.236000","article-title":"Modafinil activates phasic dopamine signaling in dorsal and ventral striata","volume":"359","author":"Bobak","year":"2016","journal-title":"J. Pharm. Exp. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2022.106474_bib60","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0304-3940(00)00813-2","article-title":"Correlation between behavior and extracellular dopamine levels in rat striatum: comparison of microdialysis and fast-scan cyclic voltammetry","volume":"281","author":"Budygin","year":"2000","journal-title":"Neurosci. Lett."},{"issue":"2\u20133","key":"10.1016\/j.phrs.2022.106474_bib61","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.neuropharm.2010.09.014","article-title":"Speedball induced changes in electrically stimulated dopamine overflow in rat nucleus accumbens","volume":"60","author":"Pattison","year":"2011","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.phrs.2022.106474_bib62","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41386-018-0292-5","article-title":"NIDA's medication development priorities in response to the Opioid Crisis: ten most wanted","volume":"44","author":"Rasmussen","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2022.106474_bib63","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.neuropharm.2017.08.008","article-title":"The great divide: separation between in vitro and in vivo effects of PSNCBAM-based CB1 receptor allosteric modulators","volume":"125","author":"Gamage","year":"2017","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.phrs.2022.106474_bib64","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.69","article-title":"Behavioral effects of the cannabinoid CB1 receptor allosteric modulator ORG27569 in rats","volume":"2","author":"Ding","year":"2014","journal-title":"Pharm. Res. Perspect."},{"issue":"2","key":"10.1016\/j.phrs.2022.106474_bib65","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/pr.54.2.323","article-title":"G protein-coupled receptor allosterism and complexing","volume":"54","author":"Christopoulos","year":"2002","journal-title":"Pharm. Rev."},{"issue":"2","key":"10.1016\/j.phrs.2022.106474_bib66","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1124\/mol.112.080879","article-title":"CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity","volume":"83","author":"Baillie","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.phrs.2022.106474_bib67","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0165-6147(92)90060-J","article-title":"Drugs of abuse: anatomy, pharmacology and function of reward pathways","volume":"13","author":"Koob","year":"1992","journal-title":"Trends Pharmacol. Sci."},{"issue":"14","key":"10.1016\/j.phrs.2022.106474_bib68","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1073\/pnas.85.14.5274","article-title":"Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats","volume":"85","author":"Di Chiara","year":"1988","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.phrs.2022.106474_bib69","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1046\/j.1471-4159.2002.01005.x","article-title":"Transient changes in mesolimbic dopamine and their association with 'reward'","volume":"82","author":"Wightman","year":"2002","journal-title":"J. Neurochem"},{"issue":"4","key":"10.1016\/j.phrs.2022.106474_bib70","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.tins.2014.02.002","article-title":"Illicit dopamine transients: reconciling actions of abused drugs","volume":"37","author":"Covey","year":"2014","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.phrs.2022.106474_bib71","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.neuropharm.2017.04.033","article-title":"Endocannabinoid modulation of dopamine neurotransmission","volume":"124","author":"Covey","year":"2017","journal-title":"Neuropharmacology"},{"issue":"18","key":"10.1016\/j.phrs.2022.106474_bib72","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1523\/JNEUROSCI.0529-04.2004","article-title":"Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats","volume":"24","author":"Cheer","year":"2004","journal-title":"J. Neurosci."},{"issue":"5","key":"10.1016\/j.phrs.2022.106474_bib73","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.neuron.2017.11.012","article-title":"Endocannabinoid actions on cortical terminals orchestrate local modulation of dopamine release in the nucleus accumbens","volume":"96","author":"Mateo","year":"2017","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.phrs.2022.106474_bib74","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1523\/JNEUROSCI.4152-06.2007","article-title":"Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation","volume":"27","author":"Cheer","year":"2007","journal-title":"J. Neurosci."},{"issue":"8","key":"10.1016\/j.phrs.2022.106474_bib75","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.neuropharm.2005.03.016","article-title":"Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction","volume":"48","author":"Lupica","year":"2005","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.phrs.2022.106474_bib76","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0306-4522(03)00070-8","article-title":"Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia","volume":"119","author":"Julian","year":"2003","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.phrs.2022.106474_bib77","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1523\/JNEUROSCI.4503-03.2004","article-title":"Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors","volume":"24","author":"Melis","year":"2004","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.phrs.2022.106474_bib78","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0896-6273(03)00021-7","article-title":"Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons","volume":"37","author":"Saal","year":"2003","journal-title":"Neuron"},{"issue":"2\u20133","key":"10.1016\/j.phrs.2022.106474_bib79","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s002130000493","article-title":"Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies","volume":"151","author":"Vanderschuren","year":"2000","journal-title":"Psychopharmacol. (Berl.)"},{"issue":"47","key":"10.1016\/j.phrs.2022.106474_bib80","doi-asserted-by":"crossref","first-page":"10707","DOI":"10.1523\/JNEUROSCI.3502-04.2004","article-title":"Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons","volume":"24","author":"Melis","year":"2004","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.phrs.2022.106474_bib81","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2174\/157015907782793612","article-title":"Endocannabinoid signaling in midbrain dopamine neurons: more than physiology?","volume":"5","author":"Melis","year":"2007","journal-title":"Curr. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106474_bib82","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0014-2999(94)90003-5","article-title":"Evidence for a bidirectional cross-tolerance between morphine and delta 9-tetrahydrocannabinol in mice","volume":"260","author":"Thorat","year":"1994","journal-title":"Eur. J. Pharm."},{"issue":"4","key":"10.1016\/j.phrs.2022.106474_bib83","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00213-005-0114-4","article-title":"Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems","volume":"182","author":"Vigano","year":"2005","journal-title":"Psychopharmacol. (Berl.)"},{"issue":"1","key":"10.1016\/j.phrs.2022.106474_bib84","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0376-8716(01)00186-7","article-title":"Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB(1) receptor binding and mRNA levels","volume":"66","author":"Gonzalez","year":"2002","journal-title":"Drug Alcohol Depend."},{"issue":"14","key":"10.1016\/j.phrs.2022.106474_bib85","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1523\/JNEUROSCI.4403-06.2007","article-title":"Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-administration","volume":"27","author":"Caille","year":"2007","journal-title":"J. Neurosci."},{"issue":"11","key":"10.1016\/j.phrs.2022.106474_bib86","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.tips.2003.09.006","article-title":"Neuroadaptive effects of active versus passive drug administration in addiction research","volume":"24","author":"Jacobs","year":"2003","journal-title":"Trends Pharm. Sci."},{"issue":"7","key":"10.1016\/j.phrs.2022.106474_bib87","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/j.1460-9568.2004.03645.x","article-title":"Changes in endocannabinoid levels in a rat model of behavioural sensitization to morphine","volume":"20","author":"Vigano","year":"2004","journal-title":"Eur. J. Neurosci."},{"issue":"3","key":"10.1016\/j.phrs.2022.106474_bib88","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1023\/A:1007058008477","article-title":"Opioid and cannabinoid receptors share a common pool of GTP-binding proteins in cotransfected cells, but not in cells which endogenously coexpress the receptors","volume":"20","author":"Shapira","year":"2000","journal-title":"Cell Mol. Neurobiol."},{"issue":"4","key":"10.1016\/j.phrs.2022.106474_bib89","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.neuropharm.2006.05.019","article-title":"Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core","volume":"51","author":"Schoffelmeer","year":"2006","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.phrs.2022.106474_bib90","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/nm.f.1869","article-title":"Endocannabinoid signaling as a synaptic circuit breaker in neurological disease","volume":"14","author":"Katona","year":"2008","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.phrs.2022.106474_bib91","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/npp.2017.126","article-title":"Endocannabinoid regulation of reward and reinforcement through interaction with dopamine and endogenous opioid signaling","volume":"43","author":"Wenzel","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"13","key":"10.1016\/j.phrs.2022.106474_bib92","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1097\/00001756-200409150-00028","article-title":"Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences","volume":"15","author":"Le Foll","year":"2004","journal-title":"Neuroreport"},{"issue":"4","key":"10.1016\/j.phrs.2022.106474_bib93","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s002130050518","article-title":"Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats","volume":"135","author":"Chaperon","year":"1998","journal-title":"Psychopharmacol. (Berl.)"},{"issue":"14","key":"10.1016\/j.phrs.2022.106474_bib94","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1523\/JNEUROSCI.21-14-05344.2001","article-title":"de Fonseca, Functional interaction between opioid and cannabinoid receptors in drug self-administration","volume":"21","author":"Navarro","year":"2001","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.phrs.2022.106474_bib95","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.brainres.2004.08.027","article-title":"A cannabinoid receptor antagonist attenuates conditioned place preference but not behavioural sensitization to morphine","volume":"1026","author":"Singh","year":"2004","journal-title":"Brain Res."},{"issue":"8","key":"10.1016\/j.phrs.2022.106474_bib96","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1097\/01.wnr.0000126217.87116.8c","article-title":"Cannabinoid agonist-induced sensitisation to morphine place preference in mice","volume":"15","author":"Manzanedo","year":"2004","journal-title":"Neuroreport"},{"key":"10.1016\/j.phrs.2022.106474_bib97","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.physbeh.2015.06.005","article-title":"Intra-accumbal CB1 receptor blockade reduced extinction and reinstatement of morphine","volume":"149","author":"Khaleghzadeh-Ahangar","year":"2015","journal-title":"Physiol. Behav."},{"issue":"1","key":"10.1016\/j.phrs.2022.106474_bib98","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bbr.2008.08.009","article-title":"Effects of CB1 receptor antagonist within the nucleus accumbens on the acquisition and expression of morphine-induced conditioned place preference in morphine-sensitized rats","volume":"197","author":"Azizi","year":"2009","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.phrs.2022.106474_bib99","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bbr.2013.03.022","article-title":"Role of intra-accumbal cannabinoid CB1 receptors in the potentiation, acquisition and expression of morphine-induced conditioned place preference","volume":"247","author":"Karimi","year":"2013","journal-title":"Behav. Brain Res"},{"issue":"2","key":"10.1016\/j.phrs.2022.106474_bib100","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0304-3940(97)13424-3","article-title":"Endogenous cannabinoids as an aversive or counter-rewarding system in the rat","volume":"223","author":"Sanudo-Pena","year":"1997","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.phrs.2022.106474_bib101","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.neuroscience.2017.07.018","article-title":"Effects of cannabinoid drugs on aversive or rewarding drug-associated memory extinction and reconsolidation","volume":"370","author":"Stern","year":"2018","journal-title":"Neuroscience"},{"issue":"1\u20133","key":"10.1016\/j.phrs.2022.106474_bib102","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ejphar.2004.08.022","article-title":"Cannabinoid receptor antagonist reduces heroin self-administration only in dependent rats","volume":"501","author":"Navarro","year":"2004","journal-title":"Eur. J. Pharm."},{"issue":"4","key":"10.1016\/j.phrs.2022.106474_bib103","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/sj.npp.1300848","article-title":"Cannabinoid modulation of opiate reinforcement through the ventral striatopallidal pathway","volume":"31","author":"Caille","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.phrs.2022.106474_bib104","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1038\/sj.npp.1301630","article-title":"Attenuation of cue-induced heroin-seeking behavior by cannabinoid CB1 antagonist infusions into the nucleus accumbens core and prefrontal cortex, but not basolateral amygdala","volume":"33","author":"Alvarez-Jaimes","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.phrs.2022.106474_bib105","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41401-018-0059-x","article-title":"Cannabinoid CB1 receptor neutral antagonist AM4113 inhibits heroin self-administration without depressive side effects in rats","volume":"40","author":"He","year":"2019","journal-title":"Acta Pharm. Sin."},{"issue":"6","key":"10.1016\/j.phrs.2022.106474_bib106","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1021\/acschemneuro.6b00310","article-title":"Enantiospecific allosteric modulation of cannabinoid 1 receptor","volume":"8","author":"Laprairie","year":"2017","journal-title":"ACS Chem. Neurosci."},{"issue":"2","key":"10.1016\/j.phrs.2022.106474_bib107","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25020417","article-title":"Allosteric cannabinoid receptor 1 (CB1) ligands reduce ocular pain and inflammation","volume":"25","author":"Thapa","year":"2020","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.phrs.2022.106474_bib108","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/s41401-018-0164-x","article-title":"Translational potential of allosteric modulators targeting the cannabinoid CB1 receptor","volume":"40","author":"Lu","year":"2019","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.phrs.2022.106474_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2020.110163","article-title":"CB1 allosteric modulators and their therapeutic potential in CNS disorders","volume":"106","author":"Mielnik","year":"2021","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2022.106474_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2019.172840","article-title":"In vivo evaluation of the CB1 allosteric modulator LDK1258 reveals CB1-receptor independent behavioral effects","volume":"190","author":"Mustafa","year":"2020","journal-title":"Pharm. Biochem Behav."},{"issue":"2","key":"10.1016\/j.phrs.2022.106474_bib111","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF02246352","article-title":"Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716","volume":"126","author":"Terranova","year":"1996","journal-title":"Psychopharmacol. (Berl.)"},{"issue":"2","key":"10.1016\/j.phrs.2022.106474_bib112","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/BF02246347","article-title":"Delta 9-tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism","volume":"126","author":"Lichtman","year":"1996","journal-title":"Psychopharmacol. (Berl.)"},{"issue":"1","key":"10.1016\/j.phrs.2022.106474_bib113","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0306-4522(99)00483-2","article-title":"Enhanced long-term potentiation in mice lacking cannabinoid CB1 receptors","volume":"95","author":"Bohme","year":"2000","journal-title":"Neuroscience"},{"issue":"6166","key":"10.1016\/j.phrs.2022.106474_bib114","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1126\/science.1243985","article-title":"Pregnenolone can protect the brain from cannabis intoxication","volume":"343","author":"Vallee","year":"2014","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.phrs.2022.106474_bib115","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1007\/s12035-018-1456-3","article-title":"Adenosine A2A-cannabinoid CB1 receptor heteromers in the hippocampus: cannabidiol blunts delta(9)-tetrahydrocannabinol-induced cognitive impairment","volume":"56","author":"Aso","year":"2019","journal-title":"Mol. Neurobiol."},{"issue":"13","key":"10.1016\/j.phrs.2022.106474_bib116","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMra1507771","article-title":"Opioid abuse in chronic pain--misconceptions and mitigation strategies","volume":"374","author":"Volkow","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.phrs.2022.106474_bib117","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/JCP.0000000000001195","article-title":"Treating opioid use disorder with a monthly subcutaneous buprenorphine depot injection: 12-month safety, tolerability, and efficacy analysis","volume":"40","author":"Andorn","year":"2020","journal-title":"J. Clin. Psychopharmacol."},{"issue":"10173","key":"10.1016\/j.phrs.2022.106474_bib118","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"R.-U.-S. Investigators, Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"Haight","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2022.106474_bib119","first-page":"859","article-title":"Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain","volume":"8","author":"Khanna","year":"2015","journal-title":"J. Pain. Res."},{"issue":"9","key":"10.1016\/j.phrs.2022.106474_bib120","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1038\/npp.2016.38","article-title":"Antidepressant-like effects of buprenorphine are mediated by kappa opioid receptors","volume":"41","author":"Falcon","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.phrs.2022.106474_bib121","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/ADM.0000000000000045","article-title":"A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world","volume":"8","author":"Lofwall","year":"2014","journal-title":"J. Addict. Med."},{"issue":"13","key":"10.1016\/j.phrs.2022.106474_bib122","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1505409","article-title":"Extended-release naltrexone to prevent opioid relapse in criminal justice offenders","volume":"374","author":"Lee","year":"2016","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.phrs.2022.106474_bib123","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/archpsyc.63.2.210","article-title":"Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial","volume":"63","author":"Comer","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"issue":"5","key":"10.1016\/j.phrs.2022.106474_bib124","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1176\/appi.ajp.2016.16050548","article-title":"Long-acting injectable naltrexone induction: a randomized trial of outpatient opioid detoxification with naltrexone versus buprenorphine","volume":"174","author":"Sullivan","year":"2017","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.phrs.2022.106474_bib125","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/2042098617744161","article-title":"Naloxone dosage for opioid reversal: current evidence and clinical implications","volume":"9","author":"Rzasa Lynn","year":"2018","journal-title":"Ther. Adv. Drug Saf."},{"issue":"5 Suppl","key":"10.1016\/j.phrs.2022.106474_bib126","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.jpainsymman.2005.01.012","article-title":"Pharmacokinetic-pharmacodynamic modeling of opioids","volume":"29","author":"Lotsch","year":"2005","journal-title":"J. Pain. Symptom Manag."},{"issue":"15","key":"10.1016\/j.phrs.2022.106474_bib127","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s40265-020-01373-1","article-title":"Non-opioid treatments for opioid use disorder: rationales and data to date","volume":"80","author":"Chalhoub","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2022.106474_bib128","series-title":"A Pharmacology Primer: Theory, Application and Methods","author":"Kenakin","year":"2009"},{"issue":"1","key":"10.1016\/j.phrs.2022.106474_bib129","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/npp.2017.140","article-title":"Sex-Dependent Effects Of Cannabis And Cannabinoids: A Translational Perspective","volume":"43","author":"Cooper","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.phrs.2022.106474_bib130","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1124\/pr.115.011163","article-title":"Sex differences in animal models: focus on addiction","volume":"68","author":"Becker","year":"2016","journal-title":"Pharm. Rev."},{"key":"10.1016\/j.phrs.2022.106474_bib131","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.expneurol.2014.01.022","article-title":"Sex differences in the neurobiology of drug addiction","volume":"259","author":"Bobzean","year":"2014","journal-title":"Exp. Neurol."},{"issue":"4","key":"10.1016\/j.phrs.2022.106474_bib132","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/YCO.0000000000000337","article-title":"Sex differences in prescription opioid use","volume":"30","author":"Serdarevic","year":"2017","journal-title":"Curr. Opin. Psychiatry"},{"issue":"1","key":"10.1016\/j.phrs.2022.106474_bib133","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.biopsych.2019.05.023","article-title":"Neurobiology of opioid addiction: opponent process, hyperkatifeia, and negative reinforcement","volume":"87","author":"Koob","year":"2020","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.phrs.2022.106474_bib134","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/npp.2009.110","article-title":"Neurocircuitry of addiction","volume":"35","author":"Koob","year":"2010","journal-title":"Neuropsychopharmacology"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822004200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822004200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:37:17Z","timestamp":1760913437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661822004200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":134,"alternative-id":["S1043661822004200"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106474","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Negative allosteric modulation of CB1 cannabinoid receptor signaling suppresses opioid-mediated reward","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106474","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106474"}}